Effect of CoQ10 on the Outcome of MAFLD Patients
Fatty Liver, NAFLD
About this trial
This is an interventional treatment trial for Fatty Liver focused on measuring Coenzyme Q10, Liver steatosis, TNF alpha, Fatty Liver, Inflammation, MAFLD, CoQ10, Ubiquinone, Liver Disease
Eligibility Criteria
Inclusion Criteria: All study subjects and prior to consenting to the ICF, laboratory and imaging work-up will be evaluated for the presence of three out of five criteria for metabolic dysregulation in the context of metabolic -dysfunction associated fatty liver disease (MAFLD): Waist circumference (WC) ≥ 102/88 cm for men and women respectively. HDL cholesterol <40 mg/dl in men and <50 mg/dl in women or on specific drug therapy. Plasma Triglycerides ≥ 150 mg/dl or on specific drug therapy. Blood pressure ≥130 and/or ≥ 85 or on specific anti-hypertensive therapy. Fasting blood glucose ≥ 100 mg/dl or on specific anti hyperglycemic therapy Patients who agree to sign an informed consent Adult patients >18 years old. Males and females Willing to comply with procedures and follow up Elevated serum transaminases (1-4 times the ULN) Imaging evidence of fatty liver: pelviabdominal ultrasound and Fibro- CAP study Exclusion Criteria: Pregnancy or lactating Physical or mental abnormalities HCV infection HBV infection Anaemia Thrombocytopenia Haematological malignancies Ongoing alcoholism (Male: >30g/day, Female: >20g/day) Patients with renal failure Autoimmune hepatitis Celiac disease Wilson's disease Hemochromatosis Drugs: Tamoxifen, Valproic acid, Amiodarone, Methotrexate, Steroids, Anticoagulants, All anti-oxidative stress agents, Cos, IUD Chronic use of systematically immunosuppressive agent or drugs that can affect liver profile. Hypo/Hyper-thyroidism Bypass surgeries TPN (Total Parenteral Nutrition)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Control group
Test Group
Patients will receive the standard conventional care which is mainly therapeutic life changes
Patients will receive Coenzyme Q10 Forte® (MEPACO Pharmaceutical Company, Cairo, Egypt) capsules in a dose of 100 mg twice per day 1 capsule every 12 hours for twelve weeks, in addition to the standard conventional care.